Singapore markets open in 5 hours 39 minutes

MeiraGTx Holdings plc (MGTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.4000+0.0900 (+2.09%)
At close: 04:00PM EDT
4.4000 0.00 (0.00%)
After hours: 04:02PM EDT

MeiraGTx Holdings plc

450 East 29th Street
14th Floor
New York, NY 10016
United States
646 860 7985
https://meiragtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 402

Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Corporate governance

MeiraGTx Holdings plc’s ISS governance QualityScore as of 1 June 2024 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.